Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Rhythm Pharmaceuticals Inc
RYTM | US
84.71
USD0.36
0.43%
RYTM | US
About Rhythm Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
84.71
Open
84.29
High
85.94
Low
83.89
Rhythm Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC) proprotein convertase subtilisin/kexin type 1 leptin receptor (LEPR) deficiency obesity and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities steroid receptor coactivator 1 deficiency obesity SH2B1 deficiency obesity MC4 receptor deficiency obesity and other MC4R disorders. The company was formerly known as Rhythm Metabolic Inc. and changed its name to Rhythm Pharmaceuticals Inc. in October 2015. Rhythm Pharmaceuticals Inc. was founded in 2008 and is headquartered in Boston Massachusetts.
View LessRYTM | US
Risk
59.0
Sharpe
0.49
Luna's Score
40/100
Recommendation
Sell
Luna says (RYTM | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
45.7%1 month
59.0%3 months
52.4%6 months
52.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
79.29
Debt to equity
6.42
Debt to assets
0.66
Ent. to EBITDA
-12.65
Ent. to rev.
28.93
PEG
-
Other Fundamentals
EBITDA
-263.94M
MarketCap
5.18B
MarketCap(USD)
5.18B
Div. yield
-
Op. margin
-139.21
Erngs. growth
-
Rev. growth
51.30
Ret. on equity
-143.42
Short ratio
17.22
Short perc.
20.42
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
10.61
Range1M
17.91
Range3M
25.49
Volumes: Market Activity
Rel. volume
0.53
Price X volume
34.64M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -12.65 | - | Cheaper |
| Ent. to Revenue | 28.93 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 79.29 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 52.36 | - | Lower Risk |
| Debt to Equity | 6.42 | -1.23 | Expensive |
| Debt to Assets | 0.66 | 0.25 | Expensive |
| Market Cap | 5.18B | - | Market Leader |
